| Cell line name |
DU145-R |
|---|
| Accession |
CVCL_C0QR |
|---|
| Resource Identification Initiative |
To cite this cell line use: DU145-R (RRID:CVCL_C0QR) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_45863; Paclitaxel (Taxol).
Derived from site: Metastatic; Brain; UBERON=UBERON_0000955. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line).
|
|---|
| Disease |
Prostate carcinoma (NCIt: C4863) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0105 (DU145) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
69Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=30244336; DOI=10.1007/s00345-018-2501-6
Hale Samli, Murat Samli, Buse Vatansever, Sena Ardicli, Nazlihan Aztopal, Deniz Dincel, Ahmet Sahin, Faruk Balci;
Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
World J. Urol. 37:1117-1126(2019) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_C0QR
|
|---|
| Encyclopedic resources |
Wikidata; Q112929465
|
|---|
| Entry history |
|---|
| Entry creation | 23-Jun-2022 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 6 |
|---|
